SENORES · Q1FY27 · earnings call
SENORES
The earnings call for Senores Pharmaceuticals Ltd's Q1FY27 highlighted the company's financial performance, including revenue growth, profitability metrics, and strategic initiatives. Management discussed their expansion plans, cost management strategies, and market opportunities. They also addressed risks related to regulatory changes and supply chain disruptions. The tone was cautiously optimistic about future growth despite current challenges.
Guidance & outlook
- The company expects continued revenue growth in the coming quarters driven by new product launches and market expansion.
Notable quotes
“We are confident in our ability to navigate current challenges and deliver sustainable growth.”— Mr. Swapnil Shah
“Our strategic initiatives are well-aligned with market demands, ensuring long-term success.”— Mr. Sanjay Majmudar
Key takeaways
- Strong focus on strategic expansion and new product launches to drive future growth.
- Acknowledgment of risks related to regulatory changes and supply chain issues.
- Confidence in cost management and ability to navigate challenges effectively.
Risks flagged
- Regulatory changes impacting the pharmaceutical industry
- Supply chain disruptions affecting production and distribution
Educational analysis only. Not investment advice. Consult a
SEBI-registered advisor before investing. Source: https://nsearchives.nseindia.com/corporate/SENORES_21072026161904_Reg_30_earningscall_SPL_final_signed.pdf
Full transcript (370 words)
Date:
July 21, 2026
To, To,
Sr. General Manager Sr. General Manager
BSE Limited National Stock Exchange of India Limited
Listing Department Listing Department
Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G
Dalal Street Bandra Kurla Complex
Mumbai – 400 001 Bandra (E), Mumbai – 400 051
BSE Scrip Code: 544319 NSE Symbol: SENORES
DSuebar.: SIinrt/iMmaadtaiomn, for Earnings Conference Call for Q1FY27
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and
Disclosure Requirements) Regulations, 2015, we hereby inform that, post announcement of Unaudited
Consolidated and Standalone Financial Results for the quarter ended June 30, 2026, the Company will
hold the earnings conference call for Q1FY27 on Monday, July 27, 2026 at 05:15 P.M. (IST).
The details of the aforesaid earnings conference call are annexed herewith.
The audio recording and transcript of the aforesaid call will be subsequently published on the website
of the Company and will be intimated accordingly.
You are requested to take the same on record.
TFohra nSkeinnogr yeosu P. harmaceuticals Limited
Deval Rajnikant Shah
Whole-Time Director & CFO
DIN: 00332722
Enclosures:
As above
Senores Pharmaceuticals Limited
1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India
P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263
Senores Pharmaceuticals Ltd
Q1FY27 Earnings Call
Monday, 27 July 2026 at 17:15 hrs (IST)
DAM Capital Advisors Ltd invites you to Senores
Pharmaceuticals Ltd’s post results conference call
Senores Pharmaceuticals Ltd’s Management Speakers
Mr. Swapnil Shah – Promoter and Managing Director
Mr. Sanjay Majmudar – Chairman
Mr. Deval Shah – Whole Time Director and Chief Financial Officer
Call Leaders
Nitin Agarwal – Analyst, DAM Capital Advisors Ltd
Dial-in Details
Universal access: +91 22 6280 1384, +91 22 7115 8285
(accessible from all networks and countries)
Diamond passcode link: click here
International timings
Hong Kong Singapore UK USA
19:45 (HKT) 19:45 (SGT) 12:45 (BST) 07:45 (EDT)
Toll free 800964448 8001012045 08081011573 18667462133
*Please dial-in at least 5-10 minutes prior to the schedule to get connected to the call in time
For further information please contact
Nitin Agarwal / Payal Shah
DAM Capital Advisors Limited
: +91 22 4202 2568 / 2638
nitin.a@damcapital.in / payal@damcapital.in